Drug developer Abraxis Biosciences Inc. has added to its large portfolio of generic drugs with U.S. regulatory approval of its generic version of Unasyn, a treatment for bacterial infections.
The U.S. Food and Drug Administration approved the injectible drug a combination of Ampicillin and Sulbactam to treat skin, skin structure, intra-abdominal and gynecological infections, the Los Angeles-based biotech said Tuesday. Unasyn maker Pfizer Inc is expected to see more than $10.4 million in sales of its brand-name version in 2005.
Abraxis shares, which closed down 19 cents to $26.78, jumped 52 cents to $27.35 in after-hours trading following the announcement.
In addition to generics, Abraxis launched its first proprietary drug, a breast cancer treatment called Abraxane, in early 2005. This is the 10th product approval Abraxis has received this year.
